Guidance for Injections of Immunotherapy Beneath the Skin for Cancer Therapy
In a significant development for cancer treatment, the Food and Drug Administration (FDA) has approved several immunotherapy medications known as PD-1 and PD-L1 inhibitors for use in the United States. These medications, which help the immune system find and kill cancer cells, are a promising advancement in the fight against cancer.
One of the recently approved subcutaneous PD-1 and PD-L1 inhibitors is Atezolizumab and hyaluronidase-tqjs, marketed as Tecentriq Hybreza. This medication, injected into fat under the skin by a cancer care professional, has been approved to treat hepatocellular carcinoma, lung cancer, and melanoma.
Another approved subcutaneous PD-1 and PD-L1 inhibitor is Nivolumab hyaluronidase-nvhy, known as Opdivo Qvantig. This medication has been approved to treat a wide range of cancers, including urothelial carcinoma, colorectal cancer, esophageal cancer, renal cell carcinoma, hepatocellular carcinoma, lung cancer, melanoma, and gastric cancer.
The FDA has also approved other PD-1 and PD-L1 inhibitors for cancer treatment beyond these two, including Pembrolizumab, Nivolumab, Atezolizumab, Durvalumab, and Avelumab. These are approved for various cancers such as non-small cell lung cancer, melanoma, renal cell carcinoma, and certain thyroid cancers, as well as newer agents like HLX43 being tested for thymic carcinoma.
It's important to note that a cancer specialist may prescribe a subcutaneous PD-1 or PD-L1 inhibitor alone or in combination with other treatments such as chemotherapy or targeted therapy. This decision is made based on the individual patient's specific circumstances and cancer type.
As research continues, more subcutaneous PD-1 or PD-L1 inhibitors may become available in the future, offering even more treatment options for those battling cancer. These innovative medications represent a significant step forward in cancer treatment, offering hope for many patients and their families.
Read also:
- visionary women of WearCheck spearheading technological advancements and catalyzing transformations
- Recognition of Exceptional Patient Care: Top Staff Honored by Medical Center Board
- A continuous command instructing an entity to halts all actions, repeated numerous times.
- Oxidative Stress in Sperm Abnormalities: Impact of Reactive Oxygen Species (ROS) on Sperm Harm
